Works matching DE "CD22 antigen"
Results: 22
Development and characterization of a camelid single‐domain antibody directed to human CD22 biomarker.
- Published in:
- Biotechnology & Applied Biochemistry, 2018, v. 65, n. 5, p. 718, doi. 10.1002/bab.1654
- By:
- Publication type:
- Article
SPECT-CT Imaging of Dog Spontaneous Diffuse Large B-Cell Lymphoma Targeting CD22 for the Implementation of a Relevant Preclinical Model for Human.
- Published in:
- Frontiers in Oncology, 2020, p. 1, doi. 10.3389/fonc.2020.00020
- By:
- Publication type:
- Article
CD8<sup>+</sup>CD122<sup>+</sup> T-cells: a newly emerging regulator with central memory cell phenotypes.
- Published in:
- Frontiers in Immunology, 2015, v. 6, p. 1, doi. 10.3389/fimmu.2015.00494
- By:
- Publication type:
- Article
Novel Targeted Therapy for Precursor B-Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.
- Published in:
- Molecular Medicine, 2016, v. 22, n. 1, p. 632, doi. 10.2119/molmed.2015.00210
- By:
- Publication type:
- Article
Profiling the Atlantic Salmon IgM<sup>+</sup> B Cell Surface Proteome: Novel Information on Teleost Fish B Cell Protein Repertoire and Identification of Potential B Cell Markers.
- Published in:
- Frontiers in Immunology, 2019, p. N.PAG, doi. 10.3389/fimmu.2019.00037
- By:
- Publication type:
- Article
CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.
- Published in:
- Frontiers in Immunology, 2018, p. 1, doi. 10.3389/fimmu.2018.00820
- By:
- Publication type:
- Article
CD22ΔE12 as a molecular target for RNAi therapy.
- Published in:
- British Journal of Haematology, 2015, v. 169, n. 3, p. 401, doi. 10.1111/bjh.13306
- By:
- Publication type:
- Article
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2014, v. 165, n. 4, p. 504, doi. 10.1111/bjh.12778
- By:
- Publication type:
- Article
CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance.
- Published in:
- Glycobiology, 2014, v. 24, n. 9, p. 807, doi. 10.1093/glycob/cwu066
- By:
- Publication type:
- Article
Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia.
- Published in:
- Toxins, 2018, v. 10, n. 5, p. 210, doi. 10.3390/toxins10050210
- By:
- Publication type:
- Article
The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.
- Published in:
- Journal of Hematology & Oncology, 2011, v. 4, n. 1, p. 49, doi. 10.1186/1756-8722-4-49
- Publication type:
- Article
N-Linked Glycosylation Regulates CD22 Organization and Function.
- Published in:
- Frontiers in Immunology, 2019, p. N.PAG, doi. 10.3389/fimmu.2019.00699
- By:
- Publication type:
- Article
Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.
- Published in:
- European Journal of Haematology, 2017, v. 98, n. 5, p. 425, doi. 10.1111/ejh.12862
- By:
- Publication type:
- Article
CD22 is required for formation of memory B cell precursors within germinal centers.
- Published in:
- PLoS ONE, 2017, v. 12, n. 3, p. 1, doi. 10.1371/journal.pone.0174661
- By:
- Publication type:
- Article
A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia.
- Published in:
- Blood & Lymphatic Cancer: Targets & Therapy, 2014, v. 4, p. 1, doi. 10.2147/BLCTT.S49048
- By:
- Publication type:
- Article
Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies.
- Published in:
- Pharmaceutics, 2018, v. 10, n. 2, p. 50, doi. 10.3390/pharmaceutics10020050
- By:
- Publication type:
- Article
High efficient expression of a functional humanized single-chain variable fragment (scFv) antibody against CD22 in Pichia pastoris.
- Published in:
- Applied Microbiology & Biotechnology, 2014, v. 98, n. 24, p. 10023, doi. 10.1007/s00253-014-6071-2
- By:
- Publication type:
- Article
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Lumoxiti a New Treatment Approved for Patients with Hairy-Cell Leukemia.
- Published in:
- Oncology Practice Management, 2018, v. 8, n. 10, p. 22
- Publication type:
- Article
A novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells.
- Published in:
- AMB Express, 2017, v. 7, n. 1, p. 1, doi. 10.1186/s13568-017-0410-5
- By:
- Publication type:
- Article
Generation of Anti-Idiotype scFv for Pharmacokinetic Measurement in Lymphoma Patients Treated with Chimera Anti-CD22 Antibody SM03.
- Published in:
- PLoS ONE, 2014, v. 9, n. 5, p. 1, doi. 10.1371/journal.pone.0096697
- By:
- Publication type:
- Article